PRA Health Sciences (PRAH) Tops Q4 EPS by 5c

PRA Health Sciences (NASDAQ: PRAH) reported Q4 EPS of $0.35, $0.05 better than the analyst estimate of $0.30. Revenue for the quarter came in at $370 million versus the consensus estimate of $323.5 million.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Halozyme adds biotech executive Appelhans to its board
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance